Synj1 (KIAA0910) as a Drug Target and Biomarker: Implications for Cancer Treatment

Target Name: SYNJ1

NCBI ID: G8867

SYNJ1

Synj1 (KIAA0910) as a Drug Target and Biomarker: Implications for Cancer Treatment

Cancer is one of the leading causes of morbidity and mortality worldwide, with over 80% of cancer deaths occurring in developed countries. The development of new treatments for cancer has become a major focus in the pharmaceutical industry, and identifying potential drug targets is a critical step in this process. One such target that has gained significant attention in recent years is SYNJ1 (KIAA0910). In this article, we will explore the potential of SYNJ1 as a drug target and biomarker for cancer treatment.

Synj1 (KIAA0910) and its Extraction

SYNJ1 is a protein that is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract. It is a member of the insulin-like growth factor (IGF) family and has been implicated in several cellular processes, including cell signaling, angiogenesis, and neuroprotection. The exact function of SYNJ1 is not well understood, but its involvement in these processes has been identified through various studies.

One of the key functions of SYNJ1 is its role in the regulation of pancreatic cancer. Studies have shown that SYNJ1 is overexpressed in pancreatic cancer tissues and that inhibition of its activity can lead to the regression of these tumors. This suggests that SYNJ1 may be a promising target for pancreatic cancer treatment.

Another function of SYNJ1 is its role in the regulation of insulin secretion. Insulin is a critical hormone that regulates glucose metabolism and is essential for maintaining normal blood sugar levels. Studies have shown that SYNJ1 is involved in the regulation of insulin secretion and that its activity is regulated by several factors, including insulin levels and glucose levels.

In addition to its role in cancer and insulin regulation, SYNJ1 has also been implicated in several other cellular processes. For example, it has been shown to play a role in cell signaling, where it can act as a negative regulator of the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and angiogenesis, and is a key factor in cancer development.

Drug Targeting Strategies

SYNJ1 is a protein that has been shown to play a critical role in several cellular processes, making it an attractive target for drug development. There are several strategies that can be used to target SYNJ1, including:

1. Small Molecule Inhibitors: One of the most common strategies for drug development is the use of small molecules to inhibit the activity of SYNJ1. This can be achieved through various methods, including inhibition of its catalytic activity, modulation of its stability, or inhibition of its interaction with other proteins.
2. mTOR Complex Inhibitors: The mTOR (mechanistic target of rapamycin) signaling pathway is involved in the regulation of cell growth, metabolism, and angiogenesis. SYNJ1 has been shown to play a role in the regulation of this pathway, and inhibition of its activity may be an effective way to target cancer cells.
3. DNA Damage Response (DDR): The DDR is a cellular process that ensures that DNA is repaired in the event of a double strand break. SYNJ1 has been shown to play a role in the regulation of the DDR, and inhibition of its activity may be an effective way to target cancer cells that are resistant to conventional chemotherapy.

Biomarker Analysis

SYNJ1 has also been used as a biomarker for cancer diagnosis and treatment. The expression of SYNJ1 has been shown to be significantly increased in various types of cancer, including pancreatic, breast, and colorectal cancers. This suggests that these cancers may be sensitive to drugs that target SYNJ1.

In addition to its use as a biomarker, SYNJ1 has also been shown to be a potential drug target in cancer treatment. Studies have shown that inhibition of SYNJ1 activity can lead to the regression of pancreatic cancer tumors in cell

Protein Name: Synaptojanin 1

Functions: Phosphatase that acts on various phosphoinositides, including phosphatidylinositol 4-phosphate, phosphatidylinositol (4,5)-bisphosphate and phosphatidylinositol (3,4,5)-trisphosphate (PubMed:27435091). Has a role in clathrin-mediated endocytosis (By similarity). Hydrolyzes PIP2 bound to actin regulatory proteins resulting in the rearrangement of actin filaments downstream of tyrosine kinase and ASH/GRB2 (By similarity)

The "SYNJ1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SYNJ1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets